Waters (NYSE:WAT) had its target price dropped by equities research analysts at Morgan Stanley from $237.00 to $218.00 in a research note issued to investors on Wednesday, April 11th. The brokerage presently has an “equal weight” rating on the medical instruments supplier’s stock. Morgan Stanley’s target price points to a potential upside of 5.01% from the stock’s current price.
Several other brokerages have also commented on WAT. Janney Montgomery Scott lifted their target price on Waters from $200.00 to $230.00 and gave the stock a “buy” rating in a research report on Wednesday, January 24th. Robert W. Baird lifted their target price on Waters from $219.00 to $220.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 24th. William Blair reiterated an “outperform” rating on shares of Waters in a research report on Tuesday, January 23rd. Zacks Investment Research downgraded Waters from a “buy” rating to a “hold” rating in a report on Saturday, January 6th. Finally, Citigroup lifted their target price on Waters from $190.00 to $223.00 and gave the company a “neutral” rating in a research note on Wednesday, January 24th. Eleven analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. Waters presently has an average rating of “Buy” and a consensus target price of $205.50.
Shares of NYSE:WAT opened at $207.60 on Wednesday. The stock has a market cap of $16,244.57, a P/E ratio of 27.49, a P/E/G ratio of 2.45 and a beta of 0.93. The company has a current ratio of 7.04, a quick ratio of 6.60 and a debt-to-equity ratio of 0.85. Waters has a one year low of $155.16 and a one year high of $220.20.
Waters (NYSE:WAT) last issued its quarterly earnings data on Tuesday, January 23rd. The medical instruments supplier reported $2.51 earnings per share for the quarter, beating analysts’ consensus estimates of $2.44 by $0.07. Waters had a return on equity of 24.70% and a net margin of 0.88%. The firm had revenue of $687.28 million during the quarter, compared to analyst estimates of $671.98 million. During the same quarter last year, the firm earned $2.21 EPS. Waters’s quarterly revenue was up 9.3% on a year-over-year basis. equities analysts forecast that Waters will post 8.18 earnings per share for the current year.
In other Waters news, SVP Mark T. Beaudouin sold 42,143 shares of the business’s stock in a transaction dated Thursday, January 25th. The stock was sold at an average price of $217.21, for a total value of $9,153,881.03. Following the transaction, the senior vice president now owns 20,749 shares in the company, valued at $4,506,890.29. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Elizabeth B. Rae sold 28,400 shares of the business’s stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $219.01, for a total value of $6,219,884.00. Following the completion of the sale, the senior vice president now directly owns 13,443 shares of the company’s stock, valued at approximately $2,944,151.43. The disclosure for this sale can be found here. Insiders have sold 73,794 shares of company stock worth $16,057,538 in the last quarter. 0.98% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Banco de Sabadell S.A bought a new position in Waters during the fourth quarter valued at about $193,000. Brown Advisory Securities LLC bought a new position in Waters during the fourth quarter valued at about $202,000. Checchi Capital Advisers LLC bought a new position in Waters during the fourth quarter valued at about $210,000. Trust Co. of Virginia VA bought a new position in Waters during the fourth quarter valued at about $213,000. Finally, Contravisory Investment Management Inc. bought a new position in Waters during the fourth quarter valued at about $290,000. 94.49% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: This report was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at https://ledgergazette.com/2018/04/18/morgan-stanley-trims-waters-wat-target-price-to-218-00.html.
Waters Corporation is an analytical instrument manufacturer. The Company operates through two segments: Waters and TA. It designs, manufactures, sells and services high performance liquid chromatography (HPLC), ultra performance liquid chromatography (UPLC and together with HPLC, referred to as LC) and mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products and post-warranty service plans.
Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with MarketBeat.com's FREE daily email newsletter.